Zhuhai Rundu Pharmaceutical (002923.SZ) issued an announcement that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration, involving the pharmaceutical "Valsartan Hydrochlorothiazide Tablets".
It is reported that Valsartan Hydrochlorothiazide Tablets were developed by Novartis and were first marketed in the United States in March 1998. This product is used to treat mild to moderate primary hypertension when single drug therapy is inadequate, and is not suitable for initial hypertension treatment.
This product obtained the "Drug Registration Certificate" from the National Medical Products Administration, indicating that the company has the qualification to sell this pharmaceutical in the domestic market, further enriching the company's product line and helping to enhance the market competitiveness of the company's products.